A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

NCT02151084 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Carcinoma
Gallbladder Carcinoma

Interventions

DRUG: Selumetinib
DRUG: Cisplatin
DRUG: Gemcitabine

Sponsor

University Health Network, Toronto